These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 8657738)

  • 1. The effect of purified extract of Fagopyrum esculentum (buckwheat) on protein kinases involved in signal transduction pathways.
    Samel D; Donnella-Deana A; de Witte P
    Planta Med; 1996 Apr; 62(2):106-10. PubMed ID: 8657738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives.
    Agostinis P; Donella-Deana A; Cuveele J; Vandenbogaerde A; Sarno S; Merlevede W; de Witte P
    Biochem Biophys Res Commun; 1996 Mar; 220(3):613-7. PubMed ID: 8607812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel contractile signal transduction pathways activated by receptors for thrombin and epidermal growth factor-urogastrone in guinea pig gastric smooth muscle: blockade by inhibitors of mitogen-activated protein kinase-kinase and phosphatidyl inositol 3'-kinase.
    Zheng XL; Renaux B; Hollenberg MD
    J Pharmacol Exp Ther; 1998 Apr; 285(1):325-34. PubMed ID: 9536028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
    Buchdunger E; Mett H; Trinks U; Regenass U; Müller M; Meyer T; Beilstein P; Wirz B; Schneider P; Traxler P
    Clin Cancer Res; 1995 Aug; 1(8):813-21. PubMed ID: 9816050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
    Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
    J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC; Keiser JA
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
    Hwang MS; Yum YN; Joo JH; Kim S; Lee KK; Gee SW; Kang HI; Kim OH
    Anticancer Res; 2001; 21(4A):2649-55. PubMed ID: 11724334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
    He S; Dibas A; Yorio T; Prasanna G
    Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition.
    Stanwell C; Burke TR; Yuspa SH
    Cancer Res; 1995 Nov; 55(21):4950-6. PubMed ID: 7585535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice.
    Yoneda T; Lyall RM; Alsina MM; Persons PE; Spada AP; Levitzki A; Zilberstein A; Mundy GR
    Cancer Res; 1991 Aug; 51(16):4430-5. PubMed ID: 1651159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
    Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
    Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
    Tuck AB; Hota C; Wilson SM; Chambers AF
    Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited selectivity of a synthetic erbstatin derivative for tyrosine kinase and cell growth inhibition.
    Treuner M; Böhmer FD; Schulze W; Petuchov SP; Grosse R
    Biochem Int; 1992 Mar; 26(4):617-25. PubMed ID: 1319149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of tyrosine kinases by alpha1A-adrenergic and growth factor receptors in transfected PC12 cells.
    Zhong H; Minneman KP
    Biochem J; 1999 Dec; 344 Pt 3(Pt 3):889-94. PubMed ID: 10585878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.